Document is current
Any future updates will be listed below
-
Authors
Ouspenskaia, Tamara http://orcid.org/0000-0002-5462-7103
Law, Travis http://orcid.org/0000-0002-7399-3299
Clauser, Karl R.
Klaeger, Susan http://orcid.org/0000-0002-0074-5163
Sarkizova, Siranush
Aguet, François http://orcid.org/0000-0001-9414-300X
Li, Bo http://orcid.org/0000-0003-0668-1620
Christian, Elena http://orcid.org/0000-0002-5593-0155
Knisbacher, Binyamin A. http://orcid.org/0000-0002-4962-9956
Le, Phuong M.
Hartigan, Christina R.
Keshishian, Hasmik
Apffel, Annie http://orcid.org/0000-0002-2209-3944
Oliveira, Giacomo http://orcid.org/0000-0001-7435-5603
Zhang, Wandi
Chen, Sarah
Chow, Yuen Ting http://orcid.org/0000-0002-9483-7324
Ji, Zhe http://orcid.org/0000-0002-1809-8099
Jungreis, Irwin http://orcid.org/0000-0002-3197-5367
Shukla, Sachet A.
Justesen, Sune
Bachireddy, Pavan
Kellis, Manolis http://orcid.org/0000-0001-7113-9630
Getz, Gad http://orcid.org/0000-0002-0936-0753
Hacohen, Nir http://orcid.org/0000-0002-2349-2656
Keskin, Derin B. http://orcid.org/0000-0002-8496-6181
Carr, Steven A.
Wu, Catherine J. http://orcid.org/0000-0002-3348-5054
Regev, Aviv http://orcid.org/0000-0003-3293-3158
-
Funding
Funding for this research was provided by:
Leukemia and Lymphoma Society
Cancer Research Institute
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (T32HG002295, U41HG007234, R01 HG004037)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (T32CA207021, R50CA211482, U24CA210979, R21 CA216772-01A1, SPORE-2P50CA101942-11A1, U24-CA210986, U01 CA214125)
European Molecular Biology Organization (ALTF 14-2018)
American-Italian Cancer Foundation
American Society of Hematology
Amy Strelzer Manasevit Grant
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (5R01HL103532)
Howard Hughes Medical Institute
- License Information
-
More Information
Article History
Received: 4 February 2020
Accepted: 16 July 2021
First Online: 18 October 2021
Competing interests
: A.R. is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics and until 31 August, 2020 was an SAB member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and ThermoFisher Scientific. From 1 August, 2020, A.R. is an employee of Genentech. C.J.W. and N.H. were cofounders, equity holders and SAB members of Neon Therapeutics, Inc. until May 2020, and now are equity holders of BionTech, Inc. D.B.K. has previously advised Neon Therapeutics, and has received consulting fees from Guidepoint, Neon Therapeutics, System Analytic Ltd and The Science Advisory Board. T.O. owns equity in BionTech, Moderna, Gilead, Novartis, Roche, 10X Genomics and Illumina. Since 3 August, 2020, T.O. is an employee of Flagship Labs 69. D.B.K. owns equity in Aduro Biotech, Agenus Inc., Armata Pharmaceuticals, Breakbio Corp., Biomarin Pharmaceutical Inc., Bristol-Myers Squibb Com., Celldex Therapeutics Inc., Editas Medicine Inc., Exelixis Inc., Gilead Sciences Inc., IMV Inc., Lexicon Pharmaceuticals Inc., and Stemline Therapeutics Inc. P.B. owns equity in Amgen Inc., Breakbio Corp., and Stemline Therapeutics Inc. S.A.S. has previously advised Neon Therapeutics and has received consulting fees from Neon Therapeutics. S.A.S. owns equity in Agenus Inc., Agios Pharmaceuticals, 152 Therapeutics, Breakbio Corp., Bristol-Myers Squibb and NewLink Genetics. S.A.C. is a SAB member of Kymera, PTM BioLabs and Seer and a scientific advisor to Pfizer and Biogen. T.O., T.L., K.R.C., S.K., N.H., D.B.K., S.A.C., C.J.W. and A.R. are coinventors on PCT/US2019/066104 directed to neoantigens and methods for identifying neoantigens as described in this paper.
